HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage

Executive Summary

Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B
Advertisement

Related Content

Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option
OSI Joins Genentech In Eye Disease Market With $935 Mil. Eyetech Purchase
Genentech Could Initiate Lucentis Rolling BLA Filing As Early As December
Pfizer/Eyetech Touting Macugen As Early Treatment Ahead Of Lucentis Entry
Lucentis Fits Genentech’s Small Market/High Need Business Model
Pfizer/Eyetech Macugen ASP
Macugen Access Program Will Help Seniors With Medicare Copay
Tarceva, Kepivance, And Macugen Approvals Are Quiet Milestones For FDA
Tarceva, Kepivance, And Macugen Approvals Are Quiet Milestones For FDA
Visudyne Medicare Settlement: CMS Cmte To Review Occult Lesion Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS045195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel